Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...

Explore the competition between Recursive and Ricursive startups in Silicon Valley aiming to build AI systems that ...

Ricursive joins Recursive and Unconventional AI in raising massive funds at multi-billion valuations out of the gate.

Kevin Cann’s "Platonic Surrealism" hits #1 on Amazon, bridging Neoplatonism and UAP phenomena with a practical ...

Ren's Vincent's Tale - Starry Night review: seven minutes of political fury ending in forced lobotomy. When enlightenment ...

AI superintelligence could be more dangerous than nuclear weapons, but importantly, nobody has built it yet. We can still ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...